50.16 USD
+1.01 (+2.05%)
50.6 USD
+0.44 (+0.88%)
Overall HROW gets a fundamental rating of 5 out of 10. We evaluated HROW against 192 industry peers in the Pharmaceuticals industry. HROW has an average financial health and profitability rating. HROW is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
HROW had positive earnings in the past year.
In the past year HROW had a positive cash flow from operations.
HROW had negative earnings in each of the past 5 years.
In multiple years HROW reported negative operating cash flow during the last 5 years.
1.2 Ratios
HROW's Return On Assets of -1.43% is fine compared to the rest of the industry. HROW outperforms 75.00% of its industry peers.
The Return On Equity of HROW (-11.06%) is better than 72.40% of its industry peers.
HROW's Return On Invested Capital of 7.42% is amongst the best of the industry. HROW outperforms 84.90% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for HROW is significantly below the industry average of 12.85%.
The last Return On Invested Capital (7.42%) for HROW is above the 3 year average (1.25%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.43% | ||
| ROE | -11.06% | ||
| ROIC | 7.42% |
ROA(3y)-7%
ROA(5y)-9.13%
ROE(3y)-36.38%
ROE(5y)-57.01%
ROIC(3y)1.25%
ROIC(5y)1.34%
1.3 Margins
Looking at the Operating Margin, with a value of 11.20%, HROW belongs to the top of the industry, outperforming 83.85% of the companies in the same industry.
HROW's Operating Margin has improved in the last couple of years.
The Gross Margin of HROW (74.56%) is better than 80.73% of its industry peers.
HROW's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.2% | ||
| PM (TTM) | N/A | ||
| GM | 74.56% |
OM growth 3Y20.76%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.21%
GM growth 5Y2.29%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so HROW is destroying value.
Compared to 1 year ago, HROW has more shares outstanding
Compared to 5 years ago, HROW has more shares outstanding
HROW has a better debt/assets ratio than last year.
2.2 Solvency
HROW has an Altman-Z score of 4.14. This indicates that HROW is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of HROW (4.14) is better than 70.83% of its industry peers.
A Debt/Equity ratio of 5.17 is on the high side and indicates that HROW has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 5.17, HROW is doing worse than 82.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.17 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.14 |
ROIC/WACC0.77
WACC9.69%
2.3 Liquidity
A Current Ratio of 2.74 indicates that HROW has no problem at all paying its short term obligations.
HROW has a Current ratio of 2.74. This is comparable to the rest of the industry: HROW outperforms 48.44% of its industry peers.
A Quick Ratio of 2.54 indicates that HROW has no problem at all paying its short term obligations.
HROW's Quick ratio of 2.54 is in line compared to the rest of the industry. HROW outperforms 52.60% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.74 | ||
| Quick Ratio | 2.54 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 109.68% over the past year.
The Revenue has grown by 47.83% in the past year. This is a very strong growth!
HROW shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 31.29% yearly.
EPS 1Y (TTM)109.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%283.33%
Revenue 1Y (TTM)47.83%
Revenue growth 3Y40.17%
Revenue growth 5Y31.29%
Sales Q2Q%45.44%
3.2 Future
Based on estimates for the next years, HROW will show a very strong growth in Earnings Per Share. The EPS will grow by 72.94% on average per year.
HROW is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 34.80% yearly.
EPS Next Y111.2%
EPS Next 2Y129.54%
EPS Next 3Y102.47%
EPS Next 5Y72.94%
Revenue Next Year39.86%
Revenue Next 2Y40.17%
Revenue Next 3Y40.21%
Revenue Next 5Y34.8%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 557.33, which means the current valuation is very expensive for HROW.
Based on the Price/Earnings ratio, HROW is valued a bit cheaper than the industry average as 75.52% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.59, HROW is valued quite expensively.
HROW is valuated quite expensively with a Price/Forward Earnings ratio of 34.88.
Based on the Price/Forward Earnings ratio, HROW is valued a bit cheaper than the industry average as 70.83% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 24.03. HROW is valued slightly more expensive when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 557.33 | ||
| Fwd PE | 34.88 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HROW indicates a somewhat cheap valuation: HROW is cheaper than 77.60% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 42.62 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of HROW may justify a higher PE ratio.
A more expensive valuation may be justified as HROW's earnings are expected to grow with 102.47% in the coming years.
PEG (NY)5.01
PEG (5Y)N/A
EPS Next 2Y129.54%
EPS Next 3Y102.47%
5. Dividend
5.1 Amount
No dividends for HROW!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
50.16
+1.01 (+2.05%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners58.14%
Inst Owner Change1.26%
Ins Owners14.44%
Ins Owner Change7.79%
Market Cap1.86B
Revenue(TTM)250.04M
Net Income(TTM)-5.20M
Analysts85.71
Price Target72.13 (43.8%)
Short Float %19.37%
Short Ratio8.44
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)819.91%
Min EPS beat(2)-18.12%
Max EPS beat(2)1657.94%
EPS beat(4)2
Avg EPS beat(4)222.09%
Min EPS beat(4)-970.3%
Max EPS beat(4)1657.94%
EPS beat(8)3
Avg EPS beat(8)30%
EPS beat(12)4
Avg EPS beat(12)-52.89%
EPS beat(16)5
Avg EPS beat(16)-847.87%
Revenue beat(2)0
Avg Revenue beat(2)-5.01%
Min Revenue beat(2)-5.31%
Max Revenue beat(2)-4.71%
Revenue beat(4)1
Avg Revenue beat(4)-5.43%
Min Revenue beat(4)-17.73%
Max Revenue beat(4)6.04%
Revenue beat(8)2
Avg Revenue beat(8)-3.74%
Revenue beat(12)4
Avg Revenue beat(12)-3.32%
Revenue beat(16)7
Avg Revenue beat(16)-1.63%
PT rev (1m)0%
PT rev (3m)18.19%
EPS NQ rev (1m)-5.23%
EPS NQ rev (3m)-17.75%
EPS NY rev (1m)-88.48%
EPS NY rev (3m)-86.39%
Revenue NQ rev (1m)-1.24%
Revenue NQ rev (3m)-7.46%
Revenue NY rev (1m)-3.38%
Revenue NY rev (3m)-3.3%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 557.33 | ||
| Fwd PE | 34.88 | ||
| P/S | 7.43 | ||
| P/FCF | N/A | ||
| P/OCF | 106.65 | ||
| P/B | 39.53 | ||
| P/tB | N/A | ||
| EV/EBITDA | 42.62 |
EPS(TTM)0.09
EY0.18%
EPS(NY)1.44
Fwd EY2.87%
FCF(TTM)-0.57
FCFYN/A
OCF(TTM)0.47
OCFY0.94%
SpS6.75
BVpS1.27
TBVpS-3.44
PEG (NY)5.01
PEG (5Y)N/A
Graham Number1.6
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.43% | ||
| ROE | -11.06% | ||
| ROCE | 9.4% | ||
| ROIC | 7.42% | ||
| ROICexc | 9.89% | ||
| ROICexgc | 44.8% | ||
| OM | 11.2% | ||
| PM (TTM) | N/A | ||
| GM | 74.56% | ||
| FCFM | N/A |
ROA(3y)-7%
ROA(5y)-9.13%
ROE(3y)-36.38%
ROE(5y)-57.01%
ROIC(3y)1.25%
ROIC(5y)1.34%
ROICexc(3y)2.44%
ROICexc(5y)3.09%
ROICexgc(3y)9.65%
ROICexgc(5y)8.28%
ROCE(3y)1.58%
ROCE(5y)1.69%
ROICexgc growth 3Y16.17%
ROICexgc growth 5YN/A
ROICexc growth 3Y-9.83%
ROICexc growth 5YN/A
OM growth 3Y20.76%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.21%
GM growth 5Y2.29%
F-Score7
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.17 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 5.21 | ||
| Cap/Depr | 207.11% | ||
| Cap/Sales | 15.47% | ||
| Interest Coverage | 1.17 | ||
| Cash Conversion | 37.33% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.74 | ||
| Quick Ratio | 2.54 | ||
| Altman-Z | 4.14 |
F-Score7
WACC9.69%
ROIC/WACC0.77
Cap/Depr(3y)562.88%
Cap/Depr(5y)365.16%
Cap/Sales(3y)46.66%
Cap/Sales(5y)28.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)109.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%283.33%
EPS Next Y111.2%
EPS Next 2Y129.54%
EPS Next 3Y102.47%
EPS Next 5Y72.94%
Revenue 1Y (TTM)47.83%
Revenue growth 3Y40.17%
Revenue growth 5Y31.29%
Sales Q2Q%45.44%
Revenue Next Year39.86%
Revenue Next 2Y40.17%
Revenue Next 3Y40.21%
Revenue Next 5Y34.8%
EBIT growth 1Y426.61%
EBIT growth 3Y69.27%
EBIT growth 5YN/A
EBIT Next Year1264.1%
EBIT Next 3Y239.32%
EBIT Next 5Y132.11%
FCF growth 1Y86.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y303.27%
OCF growth 3YN/A
OCF growth 5YN/A
HARROW INC / HROW FAQ
Can you provide the ChartMill fundamental rating for HARROW INC?
ChartMill assigns a fundamental rating of 5 / 10 to HROW.
What is the valuation status for HROW stock?
ChartMill assigns a valuation rating of 3 / 10 to HARROW INC (HROW). This can be considered as Overvalued.
Can you provide the profitability details for HARROW INC?
HARROW INC (HROW) has a profitability rating of 6 / 10.
What are the PE and PB ratios of HARROW INC (HROW) stock?
The Price/Earnings (PE) ratio for HARROW INC (HROW) is 557.33 and the Price/Book (PB) ratio is 39.53.
What is the financial health of HARROW INC (HROW) stock?
The financial health rating of HARROW INC (HROW) is 4 / 10.